M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: CT-011
Drug: Rituximab

First Posted Date: 2009-05-20

Last Posted Date: 2016-06-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00904722

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage

Phase 2

Completed

Conditions: Leukemia, Lymphocytic, Acute

Interventions: Drug: Methotrexate
Drug: Vincristine
Drug: PEG-l-asparaginase
Drug: Dexamethasone
Drug: Rituximab

First Posted Date: 2009-05-20

Last Posted Date: 2015-06-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT00905034

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

LY2275796 in Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: LY2275796

First Posted Date: 2009-05-18

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT00903708

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)

Phase 2

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Decitabine
Drug: Clofarabine

First Posted Date: 2009-05-18

Last Posted Date: 2018-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT00903760

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Male:Female Birth Ratios and Phthalate Levels

Completed

Conditions: Endocrine Diseases

Interventions: Behavioral: Questionnaire

First Posted Date: 2009-05-18

Last Posted Date: 2017-02-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 300

Registration Number: NCT00903318

Locations: 🇺🇸
Goose Creek Consolidated Independent School District, Baytown, Texas, United States
🇺🇸
Texas Southern University, Houston, Texas, United States
🇺🇸
LaJoya Independent School District, La Joya, Texas, United States

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Erlotinib Hydrochloride (Tarceva)

First Posted Date: 2009-05-18

Last Posted Date: 2015-07-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT00903734

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Dasatinib
Drug: MK-0646

First Posted Date: 2009-05-15

Last Posted Date: 2015-02-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT00903006

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

Phase 2

Terminated

Conditions: Follicular Lymphoma

Interventions: Drug: Bendamustine
Drug: Mitoxantrone
Drug: Rituximab

First Posted Date: 2009-05-14

Last Posted Date: 2020-04-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT00901927

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Urodynamic Evaluation in Post-radiation Salvage Prostatectomy Patients

Terminated

Conditions: Prostate Cancer

Interventions: Procedure: Urodynamics Test
Behavioral: Questionnaire

First Posted Date: 2009-05-13

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00901420

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Terminated

Conditions: Peritoneal Cavity Cancer
Ovarian Cancer

Interventions: Genetic: Microarray analysis
Other: Laboratory biomarker analysis

First Posted Date: 2009-05-12

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00897806

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy